← Search & browse all drugs
VARIOUS › THERAPEUTIC RADIOPHARMACEUTICALS › OTHER THERAPEUTIC RADIOPHARMACEUTICALS › Iodine (131I) compounds
iodine (131I) omburtamab
V10XA03
Forms & Strengths
- Radiopharmaceutical solution for injection: 50 mg/mL
Adult Dosing
- Intrathecal: 50 mCi administered via surgically implanted Ommaya reservoir every 4 weeks for a total of 2 doses, as part of a specific clinical protocol for neuroblastoma.
Pediatric Dosing
- Pediatric patients (≥ 1 year) Intrathecal: 50 mCi administered via Ommaya reservoir every 4 weeks for 2 doses.
Indications
- Treatment of pediatric patients aged 1 year and older with central nervous system/leptomeningeal metastases from neuroblastoma.
Mechanism of Action
- A murine monoclonal antibody (B7-H3-directed) radiolabeled with iodine-131 that binds to B7-H3 expressing tumor cells in the central nervous system, delivering localized beta and gamma radiation to induce cellular damage and apoptosis.
Contraindications
- Known hypersensitivity to omburtamab or any of its components
- Pregnancy and lactation
Adverse Reactions
- Fever
- Vomiting
- Nausea
- Musculoskeletal pain
- Headache
- Fatigue
- Thrombocytopenia
- Neutropenia
- Anemia
- Chemical meningitis
Drug Interactions
- No formal pharmacokinetic drug-drug interaction studies have been conducted with iodine (131I) omburtamab
- Concurrent administration of other myelosuppressive agents may exacerbate bone marrow suppression
Curated Content: Needs Vetting Before Put to Clinical Use